Clincosm LogoSign in Get a demo

Treatment Program for Anemia in AIDS Patients

Sponsor
R W Johnson Pharmaceutical Research Institute (Industry)
Overall Status
Completed
CT.gov ID
NCT00002022
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Condition or Disease Intervention/Treatment Phase
  • Drug: Epoetin alfa
 N/A

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Treatment Program for Anemia in AIDS Patients

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    12 Years to 0 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Exclusion Criteria

    Co-existing Condition:
    Patients with the following are excluded:

    • Life expectancy < 3 months.

    • = or < grade 4 performance score.

    • AIDS-related dementia.

    • Uncontrolled hypertension.

    • Acute symptomatic opportunistic infection or other AIDS-defining illness.

    Patients with the following are excluded:

    • Life expectancy < 3 months.

    • = or < grade 4 performance score.

    • AIDS-related dementia.

    • Uncontrolled hypertension.

    • Acute symptomatic opportunistic infection or other AIDS-defining illness.

    Patients must have:

    • A clinical diagnosis of AIDS.

    • Hematocrit < 30 percent.

    • Endogenous serum erythropoietin level = or < 500 U/ml.

    • A life expectancy = or > 3 months.

    • Grade 4 performance score.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 R W Johnson Pharmaceutical Research Institute Raritan New Jersey United States 088690602

    Sponsors and Collaborators

    • R W Johnson Pharmaceutical Research Institute

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002022
    Other Study ID Numbers:
    • 004G
    • I88-083
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    Feb 1, 1991
    Keywords provided by , ,
    Recombinant Proteins
    Drugs, Investigational
    Erythropoietin
    Acquired Immunodeficiency Syndrome
    Anemia
    Zidovudine
    Additional relevant MeSH terms:
    HIV Infections
    Anemia
    Epoetin Alfa

    Study Results

    No Results Posted as of Jun 24, 2005